Hospital Medication Review: risk and network analysis

Authors

DOI:

https://doi.org/10.30968/rbfhss.2023.144.0995

Abstract

Objective: To assess the relationship between Drug Related Problems (DRP) and its respective drugs identified from a hospital medication review (MR). Method: This is a retrospective, cross-sectional observational study based in STROBE Statement. DRP records from study period (2019-2020) were collected from a hospital MR database and classified by Pharmaceutical Care Network Europe (PCNE) standards. Through an online form, a panel of experts (pharmacists and physicians) analyzed the clinical significance of DRP included, using the Hazard Scoring Matrix (HSM). Using Gephi software, two networks were built to visualize the relationship between DRPs and drugs from the following perspectives: (i) the hospital’s pharmacists; and (ii) the panel of experts. Results: 1250 DRP related to 177 different drugs were included and compiled in 202 “DRP-drug” different combinations. According to the PCNE, 41.6% of DRP were classified as class C1 (drug selection), 20.3% as C5 (dispensing) and 13.8% as class C3 (dose selection). According to the expert panel, the “dose selection- antibiotic” combination was the one with the highest risk by HSM in the global and pharmacist analysis. To physicians, the combination “monitoring- vitamin K antagonist anticoagulants” was presented with the highest HSM. On the other hand, the “drug selection- antiulcer” combination, which was the most found in the database, was classified by the specialists with a low risk (HSM 6). Conclusion: The profile of “DRP- drug” combinations were different when compared results pre and post risk analysis. Thus, it was demonstrated that HSM can be a useful tool to improve DRP evaluation and to standardize MR services, guiding pharmacists to situations of greater clinical significance and increasing their effectiveness in improving health outcomes.

Downloads

Download data is not yet available.

References

Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm, v. 47, p. 533-43, 1990.

Foppe van Mil JW, Westerlund T, Brown L, et al. Medical care and drug-related problems: Do doctors and pharmacists speak the same language? Int J Clin Pharm. 2016;38(2):191- 194. doi:10.1007/S11096-016-0249-X/METRICS

Phillips DP, Christenfeld N, Glynn LM. Increase in US medication-error deaths between 1983 and 1993. Lancet. 1998;351(9103):643-644. doi:10.1016/S0140-6736(98)24009-8

Kohn LT, Corrigan, JM, Donaldson MS. To err is human: buil- ding a safer health system. Washington: The National Aca- demies Press, 2000. Cap. 2: Errors in health care: a leading cause of death and injury, p.26-48.

Couto RC, Pedrosa TGM. Erros acontecem: a força da transpa- rência no enfrentamento dos eventos adversos assistenciais em pacientes hospitalizados. Instituto de Estudos de Saúde Suplementar. 2016;49. Disponível em: <http://www.ismp-brasil.org/site/wp-content/uploads/2016/10/Estudo-even- tos-adversos-no-Brasil-2016.pdf> Acesso em: 20 ago. 2023.

Patel P, Zed PJ. Drug-Related Visits to the Emergency De- partment: How Big Is the Problem? Pharmacother J Hum Pharmacol Drug Ther. 2002;22(7):915-923. doi:10.1592/ PHCO.22.11.915.33630

CONSELHO FEDERAL DE FARMÁCIA (CFF). Serviços farmacêu ticos diretamente destinados ao paciente, à família e à co- munidade: contextualização e arcabouço conceitual. 2016. Disponível em: <http://www.cff.org.br/userfiles/Profar_Arca- bouco_TELA_FINAL.pdf> Acesso em: 20 ago. 2023.

Blenkinsopp A, Bond C, Raynor DK. Medication reviews. Br J Clin Pharmacol. 2012;74(4):573. doi:10.1111/J.1365-2125.2012.04331.X

Bhatt-Mehta V, Buck ML, Chung AM, et al. Recommenda- tions for Meeting the Pediatric Patient’s Need for a Clinical Pharmacist: A Joint Opinion of the Pediatrics Practice and Research Network of the American College of Clinical Phar- macy and the Pediatric Pharmacy Advocacy Group. Pharmacother J Hum Pharmacol Drug Ther. 2013;33(2):243-251. doi:10.1002/PHAR.1246

Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: Prescribing and transcribing—2013. Am J Heal Pharm. 2014;71(11):924- 942. doi:10.2146/AJHP140032

Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical Phar- macists and Inpatient Medical Care: A Systematic Review. Arch Intern Med. 2006;166(9):955-964. doi:10.1001/AR- CHINTE.166.9.955

PHARMACEUTICAL CARE NETWORK EUROPE. Classification for Drug related problems V 9.0. PCNE Classification, 2019. Disponível em: <https://www.pcne.org/upload/files/334_PCNE_classification_V9-0.pdf>. Acesso em: 20 ago. 2023.

Griese-Mammen N, Hersberger KE, Messerli M, et al. PCNE definition of medication review: reaching agreement. Int J Clin Pharm. 2018;40(5):1199-1208. doi:10.1007/S11096- 018-0696-7/FIGURES/5

Haines ST, Kliethermes MA, Sorensen TD. The Patient Care Process. “In”: DIPIRO, Joseph (ed). Pharmacotherapy: A Patho- physiologic Approach. 11 ed. McGraw Hill, 2020. Disponível em: <https://accesspharmacy.mhmedical.com/content.aspx?booki- d=2577&sectionid=219306401>. Acesso em: 20 ago. 2023.

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344-349. doi:10.1016/j.jclinepi.2007.11.008

Correr CJ, Melchiors AC, de Souza TT, Rotta I, Salgado TM, Fernandez-Llimos F. A Tool to Characterize the Components of Pharmacist Interventions in Clinical Pharmacy Services: The DEPICT Project. http://dx.doi.org/101345/aph1S006. 2013;47(7-8):946-952. doi:10.1345/APH.1S006

WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs, 2022. Oslo, Norway 2021. Disponível em: <https://www.whocc.no/atc_ddd_index/>. Acesso em: 20 ago. 2023.

Jones J, Hunter D. Consensus methods for medical and health services research. BMJ Br Med J. 1995;311(7001):376. doi:10.1136/BMJ.311.7001.376

DeRosier J, Stalhandske E, Bagian JP, Nudell T. Using health care Failure Mode and Effect Analysis: the VA National Center for Patient Safety’s prospective risk analysis system. Jt Comm J Qual Improv. 2002 May;28(5):248-67, 209. doi: 10.1016/ s1070-3241(02)28025-6.

Jacomy M, Venturini T, Heymann S, Bastian M. ForceAtlas2, a continuous graph layout algorithm for handy network visua- lization designed for the Gephi software. PLoS One. 2014 Jun 10;9(6):e98679. doi: 10.1371/journal.pone.0098679.

Michal J, Henry T, Street C. Impact of a pharmacist-driven pro- tocol to decrease proton pump inhibitor use in non-intensive care hospitalized adults. Am J Heal Pharm. 2016;73(17):S126- S132. doi:10.2146/AJHP150519

Mahmoudi L, Mohammadi R, Niknam R. Economic impact of pharmacist interventions on correction of stress-related mucosal damage prophylaxis practice. Clin Outcomes Res CEOR. 2019;11:111. doi:10.2147/CEOR.S191304

Mousavi M, Dashti-Khavidaki S, Khalili H, Farshchi A, Gatmiri M. Impact of clinical pharmacy services on stress ulcer prophylaxis prescribing and related cost in patients with renal insufficiency. Int J Pharm Pract. 2013;21(4):263-269. doi:10.1111/IJPP.12005

Fontecha-Barriuso M, Martín-Sanchez D, Martinez-Moreno JM, Cardenas-Villacres D, Carrasco S, Sanchez-Niño MD, Ruiz-Ortega M, Ortiz A, Sanz AB. Molecular pathways driving ome- prazole nephrotoxicity. Redox Biol. 2020 May;32:101464. doi: 10.1016/j.redox.2020.101464.

Barroso WKS, Rodrigues CIS, Bortolotto LA, et al. Diretrizes Brasileiras de Hipertensão Arterial – 2020. Arq Bras Cardiol. 2021;116(3):516. doi:10.36660/ABC.20201238

Wong YM, Quek YN, Tay JC, Chadachan V, Lee HK. Efficacy and safety of a pharmacist-managed inpatient anticoagulation service for warfarin initiation and titration. J Clin Pharm Ther. 2011;36(5):585-591. doi:10.1111/J.1365-2710.2010.01216.X

White RT, Bos AJ, Nawarskas JJ, et al. Inpatient pharmacy-dri- ven antithrombosis stewardship efforts on warfarin to direct oral anticoagulant conversions. JACCP J Am Coll Clin Pharm. 2023;6(3):231-240. doi:10.1002/JAC5.1759

Ahmad M, Khan AU. Global economic impact of antibiotic resistance: A review. J Glob Antimicrob Resist. 2019;19:313- 316. doi:10.1016/J.JGAR.2019.05.024

Gruenberg K, Abdoler E, O’Brien BC, Schwartz BS, MacDou- gall C. How do pharmacists select antimicrobials? A model of pharmacists’ therapeutic reasoning processes. JACCP J Am Coll Clin Pharm. 2022;5(4):398-405. doi:10.1002/JAC5.1580

Shen J, Sun Q, Zhou X, et al. Pharmacist interventions on antibiotic use in inpatients with respiratory tract infections in a Chinese hospital. Int J Clin Pharm. 2011;33(6):929-933. doi:10.1007/S11096-011-9577-Z/FIGURES/2

Fick DM, Semla TP, Steinman M, et al. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674-694. doi:10.1111/JGS.15767

Jovevski JJ, Smith CR, Roberts JL, Dev S, Iloabuchi TC, Gruber EA, Williams MJ, Slaven JE, Mitchell AM. Implementation of a compulsory clinical pharmacist-led medication deprescribing intervention in high-risk seniors in the emergency de- partment. Acad Emerg Med. 2023 Apr;30(4):410-419. doi: 10.1111/acem.14699.

Published

2024-01-08

How to Cite

1.
RAHN B, ZONZINI FH, MENDES AM. Hospital Medication Review: risk and network analysis. Rev Bras Farm Hosp Serv Saude [Internet]. 2024Jan.8 [cited 2024Feb.22];14(4):995. Available from: https://rbfhss.org.br/sbrafh/article/view/995

Issue

Section

ORIGINAL ARTICLES